酮康唑预防实验性念珠菌性阴道炎
Ketoconazole in the prevention of experimental candidal vaginitis.
作者信息
Sobel J D, Muller G
出版信息
Antimicrob Agents Chemother. 1984 Feb;25(2):281-2. doi: 10.1128/AAC.25.2.281.
Abstract
The prophylactic and therapeutic activities of ketoconazole were evaluated in rats inoculated intravaginally with Candida albicans. Daily doses of 2.5 mg/kg initiated 48 h before challenge and continued for 48 h thereafter protected 80% of the rats against infection. A similar result in rats with established infection was attained with daily doses of 5.0 mg/kg.
摘要
在经阴道接种白色念珠菌的大鼠中评估了酮康唑的预防和治疗活性。在攻击前48小时开始每日给予2.5mg/kg的剂量，并在此后持续48小时，可保护80%的大鼠免受感染。对于已感染的大鼠，每日给予5.0mg/kg的剂量也取得了类似的结果。
相似文献
1
Ketoconazole in the prevention of experimental candidal vaginitis.酮康唑预防实验性念珠菌性阴道炎
Antimicrob Agents Chemother. 1984 Feb;25(2):281-2. doi: 10.1128/AAC.25.2.281.
2
Comparison of itraconazole and ketoconazole in the treatment of experimental candidal vaginitis.伊曲康唑与酮康唑治疗实验性念珠菌性阴道炎的比较。
Antimicrob Agents Chemother. 1984 Aug;26(2):266-7. doi: 10.1128/AAC.26.2.266.
3
Management of recurrent vulvovaginal candidiasis with intermittent ketoconazole prophylaxis.
Obstet Gynecol. 1985 Mar;65(3):435-40.
4
Activity of UK-49,858, a bis-triazole derivative, against experimental infections with Candida albicans and Trichophyton mentagrophytes.双三唑衍生物UK-49,858对白色念珠菌和须癣毛癣菌实验性感染的活性。
Antimicrob Agents Chemother. 1985 May;27(5):832-5. doi: 10.1128/AAC.27.5.832.
5
Recurrent vulvovaginal candidiasis. A prospective study of the efficacy of maintenance ketoconazole therapy.
N Engl J Med. 1986 Dec 4;315(23):1455-8. doi: 10.1056/NEJM198612043152305.
6
Activity of SM-4470, a new imidazole derivative, against experimental fungal infections.新型咪唑衍生物SM - 4470对实验性真菌感染的活性
Antimicrob Agents Chemother. 1986 Sep;30(3):366-9. doi: 10.1128/AAC.30.3.366.
7
Comparison of ketoconazole, Bay N7133, and Bay L9139 in the treatment of experimental vaginal candidiasis.酮康唑、Bay N7133和Bay L9139治疗实验性阴道念珠菌病的比较。
Antimicrob Agents Chemother. 1983 Sep;24(3):434-6. doi: 10.1128/AAC.24.3.434.
8
Comparisons of ketoconazole, PR 969-566, PR 967-234, and PR 967-248 as antifungals in vitro and in the rat model of candidal vaginitis based on efficacy/safety profiles.
Ann N Y Acad Sci. 1988;544:387-91. doi: 10.1111/j.1749-6632.1988.tb40431.x.
9
The value of treating the sexual partners of women with recurrent vaginal candidiasis with ketoconazole.用酮康唑治疗复发性阴道念珠菌病女性患者性伴侣的价值。
Genitourin Med. 1992 Jun;68(3):174-6. doi: 10.1136/sti.68.3.174.
10
Synergistic anti-candidal activity of tetrandrine on ketoconazole: an experimental study.汉防己甲素与酮康唑联用的抗白色念珠菌协同作用：一项实验研究。
Planta Med. 2010 Jan;76(1):53-61. doi: 10.1055/s-0029-1185973. Epub 2009 Jul 30.
引用本文的文献
1
The vaginal mycobiome: A contemporary perspective on fungi in women's health and diseases.阴道真菌群落：关于女性健康与疾病中真菌的当代观点。
Virulence. 2017 Apr 3;8(3):342-351. doi: 10.1080/21505594.2016.1237332. Epub 2016 Sep 22.
2
In Vitro and In Vivo Activities of Essential Oil from the Seed of Anethum graveolens L. against Candida spp.胡芦巴籽油对念珠菌属的体外和体内活性
Evid Based Complement Alternat Med. 2011;2011:659704. doi: 10.1155/2011/659704. Epub 2011 May 11.
3
A novel itraconazole bioadhesive film for vaginal delivery: design, optimization, and physicodynamic characterization.一种新型的酮康唑生物粘附阴道给药制剂：设计、优化和物理动力特性研究。
AAPS PharmSciTech. 2009;10(3):951-9. doi: 10.1208/s12249-009-9288-0. Epub 2009 Jul 24.
4
Usage of antifungal drugs for therapy of genital Candida infections, purchased as over-the-counter products or by prescription: 2. Factors that may have influenced the marked changes in sales volumes during the 1990s.作为非处方药或凭处方购买的抗真菌药物用于治疗生殖器念珠菌感染的情况：2. 可能影响了20世纪90年代销售量显著变化的因素。
Infect Dis Obstet Gynecol. 2004 Jun;12(2):99-108. doi: 10.1080/10647440400003972.
5
Microscopic features of vaginal candidiasis and their relation to symptomatology.阴道念珠菌病的微观特征及其与症状学的关系。
Sex Transm Infect. 1999 Dec;75(6):417-9. doi: 10.1136/sti.75.6.417.
6
Critical role of germ tube formation in the pathogenesis of candidal vaginitis.芽管形成在念珠菌性阴道炎发病机制中的关键作用。
Infect Immun. 1984 Jun;44(3):576-80. doi: 10.1128/iai.44.3.576-580.1984.
7
Isolation of a germ-tube-forming revertant from Candida albicans B311V6.从白色念珠菌B311V6中分离出一种形成芽管的回复突变体。
Infect Immun. 1986 Jul;53(1):13-5. doi: 10.1128/iai.53.1.13-15.1986.
8
Collaborative evaluation in seven laboratories of a standardized micromethod for yeast susceptibility testing.七个实验室对酵母药敏试验标准化微量方法的协同评估。
J Clin Microbiol. 1988 Nov;26(11):2307-12. doi: 10.1128/jcm.26.11.2307-2312.1988.
9
Selection of orally active antifungal agents from 3,5-substituted isoxazolidine derivatives based on acute efficacy-safety profiles.基于急性疗效-安全性概况从3,5-取代异恶唑烷衍生物中筛选口服活性抗真菌剂。
Antimicrob Agents Chemother. 1989 Jun;33(6):895-905. doi: 10.1128/AAC.33.6.895.
本文引用的文献
1
The mechanism of action of the new antimycotic ketoconazole.新型抗真菌药酮康唑的作用机制。
Am J Med. 1983 Jan 24;74(1B):2-8. doi: 10.1016/0002-9343(83)90507-7.
2
Treatment of vaginal candidiasis with ketoconazole, a new, orally active, antimycotic.用酮康唑（一种新型口服活性抗真菌药）治疗阴道念珠菌病。
Eur J Obstet Gynecol Reprod Biol. 1979 Aug;9(4):253-9. doi: 10.1016/0028-2243(79)90065-0.
Zotero 插件